These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 36359760)
1. Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. Brennan K; Iversen KF; Blanco-Fernández A; Lund T; Plesner T; Mc Gee MM Cells; 2022 Oct; 11(21):. PubMed ID: 36359760 [TBL] [Abstract][Full Text] [Related]
2. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma. Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058 [TBL] [Abstract][Full Text] [Related]
3. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Nijhof IS; Casneuf T; van Velzen J; van Kessel B; Axel AE; Syed K; Groen RW; van Duin M; Sonneveld P; Minnema MC; Zweegman S; Chiu C; Bloem AC; Mutis T; Lokhorst HM; Sasser AK; van de Donk NW Blood; 2016 Aug; 128(7):959-70. PubMed ID: 27307294 [TBL] [Abstract][Full Text] [Related]
4. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells. Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357 [TBL] [Abstract][Full Text] [Related]
5. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease. Shrestha P; Astter Y; Davis DA; Zhou T; Yuan CM; Ramaswami R; Wang HW; Lurain K; Yarchoan R Oncoimmunology; 2023; 12(1):2163784. PubMed ID: 36632565 [TBL] [Abstract][Full Text] [Related]
6. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma. Cho N; Ko S; Shokeen M Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391 [TBL] [Abstract][Full Text] [Related]
7. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191 [TBL] [Abstract][Full Text] [Related]
8. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. Overdijk MB; Verploegen S; Bögels M; van Egmond M; Lammerts van Bueren JJ; Mutis T; Groen RW; Breij E; Martens AC; Bleeker WK; Parren PW MAbs; 2015; 7(2):311-21. PubMed ID: 25760767 [TBL] [Abstract][Full Text] [Related]
9. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Weng WK; Levy R Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782 [TBL] [Abstract][Full Text] [Related]
10. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378 [TBL] [Abstract][Full Text] [Related]
11. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Naeimi Kararoudi M; Nagai Y; Elmas E; de Souza Fernandes Pereira M; Ali SA; Imus PH; Wethington D; Borrello IM; Lee DA; Ghiaur G Blood; 2020 Nov; 136(21):2416-2427. PubMed ID: 32603414 [TBL] [Abstract][Full Text] [Related]
13. Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma. Li JW; Shi D; Wan XC; Hu J; Su YF; Zeng YP; Hu ZJ; Yu BH; Zhang QL; Wei P; Zhou XY Oncoimmunology; 2021; 10(1):1995166. PubMed ID: 34745768 [TBL] [Abstract][Full Text] [Related]
14. Levels of lymphocyte-associated regulators of complement system CD55 and CD59 are changed in schizophrenia patients. Togay A; Togay B; Ozbay Gediz D; Akbaş SH; Köksoy S Int J Psychiatry Clin Pract; 2021 Sep; 25(3):277-282. PubMed ID: 34154502 [TBL] [Abstract][Full Text] [Related]